{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:37:07Z","timestamp":1794569827567,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["4108\u201300004B"],"award-info":[{"award-number":["4108\u201300004B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8020-00414B"],"award-info":[{"award-number":["8020-00414B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8020-00414B"],"award-info":[{"award-number":["8020-00414B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["R216-A9684"],"award-info":[{"award-number":["R216-A9684"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["R216-A9684"],"award-info":[{"award-number":["R216-A9684"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["R130A5324"],"award-info":[{"award-number":["R130A5324"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-00462"],"award-info":[{"award-number":["2021-00462"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"COMPASS Pathways PLC who had no other relation to the study"},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R279-2018-1145"],"award-info":[{"award-number":["R279-2018-1145"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmental context remain unclear. Here, we tested whether a single dose of psilocybin (0.3\u2009mg\/kg) alters synaptic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen healthy participants had a psilocybin-induced psychedelic experience either inside an MRI scanner or in a therapeutic-like room. We assessed synaptic density changes by measuring the Synaptic Vesicle glycoprotein 2A in the frontal cortex and hippocampus with [\u00b9\u00b9C]UCB-J PET at baseline and one-week post-dose, and assessed subjective experiences immediately afterwards and at three months. Overall, we found no statistically significant increase in SV2A density. However, participants treated in the therapeutic-like setting exhibited more intense mystical-type experiences, longer-lasting psychological benefits, and greater increases in synaptic density than those dosed in the MRI scanner. These findings indicate that psilocybin\u2019s neuroplastic effects are modulated by environmental context, with important implications for psychedelic-assisted therapies.\n                    <jats:bold>ClinicalTrial<\/jats:bold>\n                    : NCT03289949.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-04285-y","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:26Z","timestamp":1784115446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psilocybin\u2019s effect on human brain synaptic plasticity"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-2368","authenticated-orcid":false,"given":"Annette","family":"Johansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-5641","authenticated-orcid":false,"given":"Pontus","family":"Plav\u00e9n-Sigray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Messel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8533-9132","authenticated-orcid":false,"given":"Maria","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafat","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-5224","authenticated-orcid":false,"given":"Drummond E-W.","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-279X","authenticated-orcid":false,"given":"Vincent","family":"Beliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9476-5850","authenticated-orcid":false,"given":"Alexandra","family":"Vassilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Lehel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Ozenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea S.","family":"Stenb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-0611","authenticated-orcid":false,"given":"Patrick M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Svarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-6866","authenticated-orcid":false,"given":"Gitte M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"4285_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324.","journal-title":"Nat Rev Neurosci"},{"key":"4285_CR2","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897\u2013902.","journal-title":"Neuroreport"},{"key":"4285_CR3","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol. 2019;44:1328\u201334.","journal-title":"Neuropsychopharmacol"},{"key":"4285_CR4","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25:1453\u201361.","journal-title":"J Psychopharmacol"},{"key":"4285_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"MK Madsen","year":"2020","unstructured":"Madsen MK, Fisher PM, Stenb\u00e6k DS, Kristiansen S, Burmester D, Lehel S, et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur Neuropsychopharm. 2020;33:71\u201380.","journal-title":"Eur Neuropsychopharm"},{"key":"4285_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. New Engl J Med. 2021;384:1402\u201311.","journal-title":"New Engl J Med"},{"key":"4285_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New Engl J Med. 2022;387:1637\u201348.","journal-title":"New Engl J Med"},{"key":"4285_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder. JAMA. 2023;330:843\u201353. https:\/\/doi.org\/10.1001\/jama.2023.14530.","journal-title":"JAMA"},{"key":"4285_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"4285_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289\u201399.","journal-title":"J Psychopharmacol"},{"key":"4285_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. Jama Psychiat. 2022;79:953\u201362.","journal-title":"Jama Psychiat"},{"key":"4285_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","volume":"64","author":"MK Madsen","year":"2024","unstructured":"Madsen MK, Petersen AS, Stenb\u00e6k DS, S\u00f8rensen IM, Schi\u00f8nning H, Fjeld T, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache: J Head Face Pain. 2024;64:55\u201367.","journal-title":"Headache: J Head Face Pain"},{"key":"4285_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.neubiorev.2017.03.007","volume":"77","author":"C Kraus","year":"2017","unstructured":"Kraus C, Castr\u00e9n E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity \u2013 links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev. 2017;77:317\u201326.","journal-title":"Neurosci Biobehav Rev"},{"key":"4285_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41386-022-01361-x","volume":"48","author":"GM Knudsen","year":"2023","unstructured":"Knudsen GM. Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology. 2023;48:145\u201350.","journal-title":"Neuropsychopharmacology"},{"key":"4285_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","volume":"15","author":"AK Davis","year":"2020","unstructured":"Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci. 2020;15:39\u201345.","journal-title":"J Context Behav Sci"},{"key":"4285_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109398","volume":"226","author":"RL Carhart-Harris","year":"2023","unstructured":"Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, et al. Canalization and plasticity in psychopathology. Neuropharmacology. 2023;226:109398.","journal-title":"Neuropharmacology"},{"key":"4285_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiat. 2021;11:574.","journal-title":"Transl Psychiat"},{"key":"4285_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","volume":"73","author":"A Inserra","year":"2021","unstructured":"Inserra A, Gregorio DD, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev. 2021;73:202\u201377.","journal-title":"Pharmacol Rev"},{"key":"4285_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.724606","volume":"12","author":"CMH de Vos","year":"2021","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Frontiers Psychiatry. 2021;12:724606.","journal-title":"Frontiers Psychiatry"},{"key":"4285_CR20","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1038\/s41380-023-02274-x","volume":"28","author":"AM Jaster","year":"2023","unstructured":"Jaster AM, Gonz\u00e1lez-Maeso J. Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Mol Psychiatry. 2023;28:3595\u2013612.","journal-title":"Mol Psychiatry"},{"key":"4285_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacol. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacol"},{"key":"4285_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","volume":"4","author":"C Ly","year":"2021","unstructured":"Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, et al. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacol Transl Sci. 2021;4:452\u201360.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"4285_CR23","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u20132544.e4.","journal-title":"Neuron"},{"key":"4285_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"4285_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","volume":"22","author":"NR Raval","year":"2021","unstructured":"Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int J Mol Sci. 2021;22:835.","journal-title":"Int J Mol Sci"},{"key":"4285_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin S, Chen M-K, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8:348ra96.","journal-title":"Sci Transl Med"},{"key":"4285_CR27","doi-asserted-by":"publisher","first-page":"e1750232024","DOI":"10.1523\/JNEUROSCI.1750-23.2024","volume":"44","author":"A Johansen","year":"2024","unstructured":"Johansen A, Beliveau V, Colliander E, Raval NR, Dam VH, Gillings N, et al. An in vivo high-resolution human brain atlas of synaptic density. J Neurosci. 2024;44:e1750232024.","journal-title":"J Neurosci"},{"key":"4285_CR28","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/s41380-023-02285-8","volume":"28","author":"A Johansen","year":"2023","unstructured":"Johansen A, Armand S, Plav\u00e9n-Sigray P, Nasser A, Ozenne B, Petersen IN, et al. Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. Mol Psychiatry. 2023;28:4272\u20139.","journal-title":"Mol Psychiatry"},{"key":"4285_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/02791072.2024.2302186","volume":"57","author":"OR Hovmand","year":"2025","unstructured":"Hovmand OR, Jensen ME, Juul TS, Madsen MK, Fisher PM, Stenb\u00e6k DS. Validation of the Danish translation of the revised Mystical Experience Questionnaire (MEQ30) and possible impact of setting, dose and intention. J Psychoact Drugs. 2025;57:37\u201346.","journal-title":"J Psychoact Drugs"},{"key":"4285_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1177\/02698811241269669","volume":"38","author":"OR Hovmand","year":"2024","unstructured":"Hovmand OR, Madsen MK, Fisher PM, Stenb\u00e6k DS. Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire. J Psychopharmacol. 2024;38:924\u201332.","journal-title":"J Psychopharmacol"},{"key":"4285_CR31","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165\u201380.","journal-title":"J Psychopharmacol"},{"key":"4285_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974.","journal-title":"Front Pharmacol"},{"key":"4285_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jad.2024.12.061","volume":"372","author":"GM Goodwin","year":"2025","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, et al. The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. J Affect Disord. 2025;372:523\u201332.","journal-title":"J Affect Disord"},{"key":"4285_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.841648","volume":"13","author":"DE-W McCulloch","year":"2022","unstructured":"McCulloch DE-W, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Front Pharmacol. 2022;13:841648.","journal-title":"Front Pharmacol"},{"key":"4285_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.873455","volume":"13","author":"C Messell","year":"2022","unstructured":"Messell C, Summer L, Bonde LO, Beck BD, Stenb\u00e6k DS. Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. Front Psychol. 2022;13:873455.","journal-title":"Front Psychol"},{"key":"4285_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268\u201383.","journal-title":"Psychopharmacology"},{"key":"4285_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00664-8","volume":"10","author":"J Tjerkaski","year":"2020","unstructured":"Tjerkaski J, Cervenka S, Farde L, Matheson GJ. Kinfitr \u2014 an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. EJNMMI Res. 2020;10:77.","journal-title":"EJNMMI Res"},{"key":"4285_CR38","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00180-012-0344-y","volume":"28","author":"KK Holst","year":"2013","unstructured":"Holst KK, Budtz-J\u00f8rgensen E. Linear latent variable models: the lava-package. Comput Stat. 2013;28:1385\u2013452.","journal-title":"Comput Stat"},{"key":"4285_CR39","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/rssc.12414","volume":"69","author":"B Ozenne","year":"2020","unstructured":"Ozenne B, Fisher PM, Budtz-J\u2298rgensen E. Small sample corrections for Wald tests in latent variable models. J R Stat Soc: Ser C (Appl Stat). 2020;69:841\u201361.","journal-title":"J R Stat Soc: Ser C (Appl Stat)"},{"key":"4285_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.948729","volume":"13","author":"A S\u00f8ndergaard","year":"2022","unstructured":"S\u00f8ndergaard A, Madsen MK, Ozenne B, Armand S, Knudsen GM, Fisher PM, et al. Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Front Psychol. 2022;13:948729.","journal-title":"Front Psychol"},{"key":"4285_CR41","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/jnc.13687","volume":"139","author":"D Fernandes","year":"2016","unstructured":"Fernandes D, Carvalho AL. Mechanisms of homeostatic plasticity in the excitatory synapse. J Neurochem. 2016;139:973\u201396.","journal-title":"J Neurochem"},{"key":"4285_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09562-7","volume":"10","author":"SE Holmes","year":"2019","unstructured":"Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.","journal-title":"Nat Commun"},{"key":"4285_CR43","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41380-022-01465-2","volume":"27","author":"SE Holmes","year":"2022","unstructured":"Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatr. 2022;27:2273\u201381.","journal-title":"Mol Psychiatr"},{"key":"4285_CR44","doi-asserted-by":"publisher","first-page":"e13123","DOI":"10.1111\/adb.13123","volume":"27","author":"GA Angarita","year":"2022","unstructured":"Angarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li CR, et al. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: an exploratory 11C-UCB-J positron emission tomography study in humans. Addict Biol. 2022;27:e13123.","journal-title":"Addict Biol"},{"key":"4285_CR45","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1038\/s41380-020-00891-4","volume":"26","author":"DC D\u2019Souza","year":"2021","unstructured":"D\u2019Souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, et al. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Mol Psychiatr. 2021;26:3192\u20133200.","journal-title":"Mol Psychiatr"},{"key":"4285_CR46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00259-020-05149-3","volume":"48","author":"S Li","year":"2021","unstructured":"Li S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, et al. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol I. 2021;48:1327\u201338.","journal-title":"Eur J Nucl Med Mol I"},{"key":"4285_CR47","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/0271678X20964248","volume":"41","author":"H Tuncel","year":"2020","unstructured":"Tuncel H, Boellaard R, Coomans EM, de Vries EF, Glaudemans AW, Feltes PK, et al. Kinetics and 28-day test\u2013retest repeatability and reproducibility of [11C]UCB-J PET brain imaging. J Cereb Blood Flow Metabolism. 2020;41:1338\u201350.","journal-title":"J Cereb Blood Flow Metabolism"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04285-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04285-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:17:52Z","timestamp":1791508672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04285-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4285"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04285-y","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GMK has been a speaker for Cybin and H Lundbeck and been a consultant for Sanos, Onsero, Pangea, Gilgamesh, Seaport and Abbvie within the last three years. MKM is affiliated as a scientific advisor to Lobe Sci. All other authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"544"}}